These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 36865925)

  • 1. Toripalimab plus chemotherapy vs. chemotherapy in patients with advanced non-small-cell lung cancer: A cost-effectiveness analysis.
    Huo G; Liu W; Kang S; Chen P
    Front Pharmacol; 2023; 14():1131219. PubMed ID: 36865925
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness analysis of toripalimab plus chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer in China.
    Zhang M; Xu K; Lin Y; Zhou C; Bao Y; Zhang L; Li X
    Front Immunol; 2023; 14():1169752. PubMed ID: 37313403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarkers-Based Cost-Effectiveness of Toripalimab Plus Chemotherapy for Patients with Treatment-Naive Advanced Non-Small Cell Lung Cancer.
    Zhang H; Li L; Feng L; Zhou Z; Zhang X; Feng J; Liu Q
    Adv Ther; 2023 Nov; 40(11):4945-4956. PubMed ID: 37715852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of camrelizumab plus chemotherapy as first-line treatment for advanced squamous NSCLC in China.
    Shao T; Ren Y; Zhao M; Tang W
    Front Public Health; 2022; 10():912921. PubMed ID: 36045725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of toripalimab plus chemotherapy as the first-line treatment in patients with advanced non-small cell lung cancer (NSCLC) without EGFR or ALK driver mutations from the Chinese perspective.
    Zhou K; Shu P; Zheng H; Li Q
    Front Pharmacol; 2023; 14():1133085. PubMed ID: 37266153
    [No Abstract]   [Full Text] [Related]  

  • 6. A cost-effectiveness analysis of first-line toripalimab plus chemotherapy in advanced nonsquamous non-small cell lung cancer in China.
    Zheng Z; Zhu G; Cao X; Cai H; Zhu H
    Expert Rev Clin Pharmacol; 2023 Mar; 16(3):267-273. PubMed ID: 36877089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC.
    Chen P; Wang X; Zhu S; Li H; Rui M; Wang Y; Sun H; Ma A
    Front Public Health; 2022; 10():956792. PubMed ID: 36016894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non-small cell lung cancer in China.
    Liu H; Wang Y; He Q
    Health Econ Rev; 2022 Dec; 12(1):66. PubMed ID: 36581793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of nivolumab plus ipilimumab versus chemotherapy as first-line therapy in advanced non-small cell lung cancer.
    Shu Y; Ding Y; Li F; Zhang Q
    Int Immunopharmacol; 2023 Jan; 114():109589. PubMed ID: 36700770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of sugemalimab in combination with chemotherapy as first-line treatment in Chinese patients with metastatic NSCLC.
    Chen P; Li Y; Jing X; Chen J; Chen S; Yang Q
    Lung Cancer; 2022 Dec; 174():157-164. PubMed ID: 36413882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy alone as first-line treatment of locally advanced or metastatic oesophageal squamous cell carcinoma.
    Liu L; Wang L; Chen L; Ding Y; Zhang Q; Shu Y
    Front Immunol; 2023; 14():1092385. PubMed ID: 36756110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic evaluation of toripalimab combined with chemotherapy in the treatment of non-small cell lung cancer.
    Wang H; Long Y; Xu Y; Liao L; Zhou Y
    Front Public Health; 2023; 11():1137255. PubMed ID: 37033059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
    Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
    Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic Evaluation of First-Line Camrelizumab for Advanced Non-small-cell Lung Cancer in China.
    Xiang G; Gu L; Chen X; Wang F; Chen B; Zhao J; Lu Y; Chang F; Zhu Y
    Front Public Health; 2021; 9():743558. PubMed ID: 34957008
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
    Wu B; Chen H; Shen J; Ye M
    Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line tremelimumab plus durvalumab and chemotherapy
    Liu W; Huo G; Chen P
    Front Pharmacol; 2023; 14():1163381. PubMed ID: 37547328
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-Utility Analysis of Camrelizumab Plus Chemotherapy Versus Chemotherapy Alone as a First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer in China.
    Chen T; Xie R; Zhao Q; Cai H; Yang L
    Front Oncol; 2022; 12():746526. PubMed ID: 35936702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness Analysis of Sintilimab Plus Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer: A Societal Perspective.
    Li F; Chen Y; Xiao D; Jiang S; Yang Y
    Adv Ther; 2024 Apr; 41(4):1436-1449. PubMed ID: 38356107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness evaluation based on two models of first-line atezolizumab monotherapy and chemotherapy for advanced non-small cell lung cancer with high-PDL1 expression.
    Zhang C; Liu Y; Tan J; Tian P; Li W
    Front Oncol; 2023; 13():1093469. PubMed ID: 36998459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of nivolumab in patients with NSCLC in the United States.
    Chaudhary MA; Lubinga SJ; Smare C; Hertel N; Penrod JR
    Am J Manag Care; 2021 Aug; 27(8):e254-e260. PubMed ID: 34460179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.